Redpoint Investment Management Pty Ltd lifted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,573 shares of the medical equipment provider’s stock after acquiring an additional 4,411 shares during the period. Redpoint Investment Management Pty Ltd’s holdings in Boston Scientific were worth $3,660,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of BSX. We Are One Seven LLC bought a new position in Boston Scientific in the fourth quarter valued at $27,000. Ipswich Investment Management Co. Inc. bought a new position in Boston Scientific in the fourth quarter valued at $28,000. CWM LLC grew its position in Boston Scientific by 54.3% in the fourth quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 359 shares in the last quarter. West Oak Capital LLC grew its position in Boston Scientific by 40.0% in the fourth quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 300 shares in the last quarter. Finally, Exane Derivatives grew its position in Boston Scientific by 116,300.0% in the fourth quarter. Exane Derivatives now owns 1,164 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 1,163 shares in the last quarter. 91.60% of the stock is owned by institutional investors.

In other news, EVP David A. Pierce sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $38.15, for a total transaction of $190,750.00. Following the completion of the sale, the executive vice president now owns 29,201 shares in the company, valued at approximately $1,114,018.15. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 6,143 shares of Boston Scientific stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $37.13, for a total transaction of $228,089.59. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,724 shares of company stock valued at $3,350,373. 0.73% of the stock is currently owned by corporate insiders.

NYSE BSX opened at $39.19 on Monday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.58. The stock has a market cap of $54.23 billion, a PE ratio of 26.66, a P/E/G ratio of 2.30 and a beta of 0.83. Boston Scientific Co. has a 52-week low of $25.04 and a 52-week high of $39.44.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 6th. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.02. The company had revenue of $2.56 billion during the quarter, compared to analysts’ expectations of $2.57 billion. Boston Scientific had a net margin of 17.01% and a return on equity of 26.80%. Boston Scientific’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.34 EPS. As a group, equities research analysts expect that Boston Scientific Co. will post 1.56 earnings per share for the current year.

BSX has been the subject of a number of analyst reports. Argus raised their target price on shares of Boston Scientific from $41.00 to $43.00 and gave the company a “buy” rating in a research report on Friday, October 26th. Guggenheim raised their target price on shares of Boston Scientific to $45.00 and gave the company a “buy” rating in a research report on Friday, November 16th. Zacks Investment Research downgraded shares of Boston Scientific from a “hold” rating to a “sell” rating in a research report on Monday, December 31st. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 price target on shares of Boston Scientific in a research note on Wednesday, February 6th. Finally, Barclays initiated coverage on shares of Boston Scientific in a research note on Monday, October 15th. They issued an “overweight” rating and a $43.00 price target for the company. Three analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and two have issued a strong buy rating to the stock. Boston Scientific presently has a consensus rating of “Buy” and an average target price of $40.35.

TRADEMARK VIOLATION WARNING: “Redpoint Investment Management Pty Ltd Raises Stake in Boston Scientific Co. (BSX)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2019/02/11/redpoint-investment-management-pty-ltd-raises-stake-in-boston-scientific-co-bsx.html.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Recommended Story: How analysts view the yield curve

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.